Compare NHTC & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHTC | IFRX |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 86.0M |
| IPO Year | 1995 | 2017 |
| Metric | NHTC | IFRX |
|---|---|---|
| Price | $2.79 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 67.5K | ★ 6.5M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 28.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,873,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,075.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.40 | $0.71 |
| 52 Week High | $6.00 | $2.77 |
| Indicator | NHTC | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.95 | 43.05 |
| Support Level | $2.71 | $0.92 |
| Resistance Level | $3.07 | $1.12 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 23.15 | 39.73 |
Natural Health Trends Corp is an international direct-selling and e-commerce company. It offers a line of products such as Wellness, Herbal, Beauty, Lifestyle, and Home. Wellness products include targeted nutrition for joint health, antioxidant support, digestive health, heart health, and vision health. Herbal products include anti-aging and hydrating cleansers, creams, lotions, serums, and toners. Lifestyle products improve the overall quality of life and to support active, physical and healthy lifestyles. Home products are designed to create a clean and natural living environment for the home. It generates a majority of its revenue from Hong Kong and rest from China, Taiwan, Japan, United States and other regions.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.